Skip to content

DRUGS MADE IN AMERICA ACQ II CORP

US · DMII #3572 by market cap
10.23 -0.02 -0.20%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:04

Valuation each multiple against its own 5-year range

P/B ratio 1.32 In line with history 61st percentile
5-year average 1.32 · #82 of 308 in Shell Companies
P/E ratio 35.07 In line with history 65th percentile
5-year average 41.87 · #10 of 97 in Shell Companies
P/S ratio --
5-year average 0.00

Vs. peers Shell Companies

Company Market cap P/E (TTM) P/B Div yield
DRUGS MADE IN AMERICA ACQ II CORP (DMII) 651.65M 27.65 1.30 0.00%
Vylor Inc (VYLR) 45.44B 96.04 2.99 0.00%
Churchill Capital Corp XI (CCXI) 627.18M 0.00 2.34 0.00%
EQV VENTURES ACQUISITION CORP. II (EVAC) 609.61M 35.97 1.31 0.00%
Bain Capital GSS Investment (BCSS) 599.18M 0.00 1.30 0.00%
Cantor Equity Partners IV (CEPF) 590.36M 30.38 1.27 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value9.85 Economic moatNarrow UncertaintyHigh

Trading 3.7% above Morningstar's fair value estimate.

Fair value

Drugs Made In America Acquisition II Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% premium over our quantitative fair value estimate of $9.85 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's lack of profitability weakens our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of 2.8% lies in the bottom 45% globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are overvalued.

Conversely, the company's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 76.3%, a core component of valuation, ranks in the top 45% globally. The market price is low relative to the book (accounting) value of the company's equity, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 16:04:04 · For reference only, not investment advice and not tailored to your situation.

DRUGS MADE IN AMERICA ACQ II CORP discussion 0 comments

Add a comment